GALT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast GALT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GALT is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 6.100

Low

6.00

Averages

6.00

High

6.00

Current: 6.100

Low

6.00

Averages

6.00

High

6.00

H.C. Wainwright

Buy

initiated

2025-06-18

Reason

H.C. Wainwright

Price Target

2025-06-18

initiated

Buy

Reason

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2025-04-02

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2025-04-02

Reiterates

Hold

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Hold

Downgrades

n/a

2024-12-27

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2024-12-27

Downgrades

Strong Buy

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Galectin Therapeutics Inc (GALT.O) is -14.51, compared to its 5-year average forward P/E of -3.54. For a more detailed relative valuation and DCF analysis to assess Galectin Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.54

Current PE

-14.51

Overvalued PE

-1.06

Undervalued PE

-6.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.04

Current PS

0.00

Overvalued PS

5.64

Undervalued PS

-3.55

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GALT News & Events

Events Timeline

No data

News

2.0

09-25Benzinga

Stitch Fix Reports Q4 Earnings, Alongside Transocean, MBX Biosciences, and Other Major Stocks Declining in Thursday's Pre-Market Trading

2.0

09-12NASDAQ.COM

Galectin Therapeutics Inc. (GALT) Sees 7.48% Increase Over the Past Week: Key Insights

9.0

09-12NASDAQ.COM

Stocks of MODD, GALT, XCUR, PEPG, and BSGM Surge in After-Hours Trading Following Clinical Developments and Strategic Actions

People Also Watch

Frequently Asked Questions

What is Galectin Therapeutics Inc (GALT) stock price today?

The current price of GALT is 6.1 USD — it has decreased -2.4 % in the last trading day.

What is Galectin Therapeutics Inc (GALT)'s business?

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

What is the price predicton of GALT Stock?

What is Galectin Therapeutics Inc (GALT)'s revenue for the last quarter?

Galectin Therapeutics Inc revenue for the last quarter amounts to -4.20M USD, decreased -53.70 % YoY.

What is Galectin Therapeutics Inc (GALT)'s earnings per share (EPS) for the last quarter?

Galectin Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Galectin Therapeutics Inc (GALT)'s fundamentals?

The market is revising No Change the revenue expectations for Galectin Therapeutics Inc. (GALT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 35.56%.

How many employees does Galectin Therapeutics Inc (GALT). have?

Galectin Therapeutics Inc (GALT) has 15 emplpoyees as of December 15 2025.

What is Galectin Therapeutics Inc (GALT) market cap?

Today GALT has the market capitalization of 402.95M USD.